Publication | Open Access

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer

Acquired ResistanceMedicineVaried Dosing SchedulesPharmacologyBronchial NeoplasmPharmacotherapyAnti-cancer AgentEgfr-mutant Lung CancerLung CancerCancer TreatmentOncologyRadiation OncologyTumor Microenvironment